Webinar | Cardiovascular Ultrasound| August 27, 2021

WEBINAR: Echocardiographic Strain Assessment in a Contemporary Cardiology Practice

Sponsored by Siemens and Epsilon Imaging

Siemens now seamlessly integrates Epsilon Imaging's strain echo software.

This educational webinar is focused on the value echocardiographic strain imaging brings to a contemporary cardiology practice presented by Anya Narezkina, M.D. She is an assistant clinical professor, Division of Cardiovascular Medicine and director of the Cardio-Oncology Program at the University of California San Diego Cardiovascular Institute. 


The webinar takes place Sept. 21, at 3 p.m. eastern time / 2 p.m. central time.


The webinar will cover the importance of myocardial strain imaging and current guidelines recommended by the American Society of Echocardiography (ASE). Additionally, it will focus on the development of a comprehensive cardio-oncology program and the utility of strain imaging for diagnostic and surveillance for cardiotoxicity as well as other clinical indications. The webinar will conclude with a look into the future of strain imaging for echocardiography, followed by a Q & A session.


Register for this Webinar



Learning Objectives:

• Staying abreast of the current guidelines on strain imaging

• Understanding the utility of echo strain assessment in clinical practice

• Proper utilization of strain applications in cardio-oncology

• Understanding the value of strain imaging for prognostication in the clinical setting



Speaker Profile:

Anya Narezkina, M.D. Assistant Clinical Professor, Division of Cardiovascular Medicine Director of the Cardio-Oncology Program University of California San Diego Cardiovascular InstituteAnya Narezkina, M.D.
Assistant Clinical Professor, Division of Cardiovascular Medicine

Director of the Cardio-Oncology Program

University of California San Diego Cardiovascular Institute


Narezkina is a board-certified cardiologist who specializes in cardio-oncology. As director of the cardio-oncology program at UC San Diego Health, She works in close collaboration with oncologists to address the heart needs of patients undergoing chemotherapy, targeted cancer therapy, immunotherapy, radiation therapy or bone marrow transplantation. Her research has focused on understanding risks of cardiac complications with cancer therapies.


Narezkina also collaborates with bioengineering department at UC San Diego on developing novel imaging approaches for early diagnosis of cardiotoxicity in patients treated with chemotherapy. 


She completed a fellowship in cardiology and a residency in internal medicine and at UC San Diego School of Medicine. She earned her medical degree from the Smolensk State Medical Academy in Russia. She is board certified in internal medicine and cardiovascular disease. Narezkina is also certified by the National Board of Echocardiography in adult comprehensive echocardiography.



Company Profiles:


Epsilon Imaging

Epsilon Imaging is a provider of workflow enhancing solutions for cardiology based in Ann Arbor, Michigan, USA, and is transforming cardiac diagnostic workflow with a vendor neutral suite of software applications designed for echocardiography. EchoInsight provides a suite of clinical applications that provide visualization and analysis with practical strain imaging for the clinical environment. Applications assist clinicians to improve, standardize, and streamline interpretation and reporting of echo studies. Clinical applications include LV, LV Contrast, RV, Full Heart and Stress Echo.


Siemens Healthineers

At Siemens Healthineers, our purpose is to enable healthcare providers to increase value by empowering them on their journey toward expanding precision medicine, transforming care delivery, and improving patient experience, all made possible by digitalizing healthcare. An estimated 5 million patients globally benefit every day from our innovative technologies and services in the areas of diagnostic and therapeutic imaging, laboratory diagnostics, and molecular medicine, as well as digital health and enterprise services. We are a leading medical technology company with over 120 years of experience and 18,500 patents globally. Through the dedication of more than 50,000 dedicated colleagues in 70 countries, we will continue to innovate and shape the future of healthcare.


Register for this Webinar


Related Content

An example of cardiac ultrasound longitudinal strain measurements on the Epsilon EchoInsight software. This can be used to assess cardiotoxicity from chemotherapy agents.  Cardio-oncology

An example of cardiac ultrasound longitudinal strain measurements on the Epsilon EchoInsight software. This can be used to assess cardiotoxicity from chemotherapy agents. 

News | Cardio-oncology | February 25, 2021
February 25, 2020 — Results of a multi-centre, international, clinical trial co-led by Peter Munk Cardiac Centre (PMC
Statins Reduce Stroke, Cardiovascular Risk in Cancer Patients Following Radiation
News | Cardio-oncology | July 29, 2019
Cancer patients taking cholesterol-lowering statin medication following radiation therapy of the chest, neck or head...
CT, Mammograms Offer Clues to Preventing Heart Problems After Cancer Treatment
News | Cardio-oncology | March 13, 2019
An imaging procedure commonly performed before starting cancer treatment can provide valuable clues about a patient's...
ACC Hosts Third Annual Cardio-Oncology Course
News | Cardio-oncology | January 28, 2019
The American College of Cardiology host the third Advancing the Cardiovascular Care of the Oncology Patient course in...
Breast Cancer Patients Have Less Heart Damage With Heart Drug and Trastuzumab
News | Cardio-oncology | January 03, 2019
Breast cancer patients who take a heart drug at the same time as trastuzumab have less heart damage, according to a...
Heart Attack, Stroke Risks Increase Leading Up to Cancer Diagnosis
News | Cardio-oncology | December 21, 2018
Older adults with cancer are more likely to have had a heart attack or stroke in the months prior to their cancer...
Xarelto Reduces Blood Clot Events in High-Risk Cancer Patients
News | Cardio-oncology | December 07, 2018
New data from the Phase 3 CASSINI study showed a 60 percent reduction of venous thromboembolism (VTE, or blood clot)...
Beta Blocker Shows Mixed Results in Protecting Against Chemo-Induced Heart Damage
News | Cardio-oncology | March 14, 2018
After six months of follow-up, women newly diagnosed with breast cancer who were given the beta blocker carvedilol to...